Metformin mitigates potassium bromate-induced liver grievance in rat through attenuating NF-kB and PI3K/Akt pathway
Background: Metformin (MET) is a dietary polyphenolic compound that exhibits anti-inflammatory and antioxidant properties. This study evaluated the protective effects of MET in both in vitro and in vivo models against potassium bromate (KBrO3)-induced hepatotoxicity. Hepatic cells were exposed to KB...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Electronic Journal of Biotechnology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0717345825000144 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849319723880153088 |
|---|---|
| author | Bo Ma Sheng Zheng Ning Xie Juan Yang Xueli Zeng Pei Liu Shunling Zhang Ji Li |
| author_facet | Bo Ma Sheng Zheng Ning Xie Juan Yang Xueli Zeng Pei Liu Shunling Zhang Ji Li |
| author_sort | Bo Ma |
| collection | DOAJ |
| description | Background: Metformin (MET) is a dietary polyphenolic compound that exhibits anti-inflammatory and antioxidant properties. This study evaluated the protective effects of MET in both in vitro and in vivo models against potassium bromate (KBrO3)-induced hepatotoxicity. Hepatic cells were exposed to KBrO3 with or without metformin (20, 40, and 60 µM), and cell viability and Reactive Oxygen Species levels were assessed. In vivo, rats were divided into five groups: control, KBrO3, and KBrO3 with metformin (25, 50, and 100 mg/kg). Liver and blood samples were analyzed for histological changes, oxidative stress markers, lipid peroxidation, liver enzymes, and PI3K/Akt signaling. Results: KBrO3 exposure significantly decreased cell viability and increased ROS levels. Co-treatment with MET dose-dependently restored cell viability, with 60 µM MET achieving approximately 80% viability. Metformin also reduced ROS levels, with mean fluorescence intensity approaching control values at higher concentrations. In the in vivo study, KBrO3 exposure elevated lipid peroxidation markers, depleted antioxidant enzyme activities, and triggered oxidative stress and inflammation. Metformin significantly alleviated histological liver damage, suppressed proinflammatory cytokines, enhanced antioxidant enzyme activities, and modulated the PI3K/Akt signaling pathway to promote cell survival and reduce oxidative injury. Conclusions: Metformin effectively protects hepatic cells against KBrO3-induced cytotoxicity by improving cell viability and reducing Reactive Oxygen Species levels. Metformin successfully mitigates KBrO3-induced hepatic injury by reducing oxidative stress, modulating inflammatory pathways (NF-kB), and regulating the PI3K/Akt signaling cascade, offering molecular evidence of its hepatoprotective effects.How to cite: Ma B, Zheng S, Xie N, et al. Metformin mitigates potassium bromate induced liver grievance in rat through attenuating NF-kB and PI3K/Akt pathway. Electron J Biotechnol 2025;76. https://doi.org/10.1016/j.ejbt.2025.03.002. |
| format | Article |
| id | doaj-art-8717b90ef3d34d84a0fa43d3a5528f71 |
| institution | Kabale University |
| issn | 0717-3458 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Electronic Journal of Biotechnology |
| spelling | doaj-art-8717b90ef3d34d84a0fa43d3a5528f712025-08-20T03:50:21ZengElsevierElectronic Journal of Biotechnology0717-34582025-07-017611110.1016/j.ejbt.2025.03.002Metformin mitigates potassium bromate-induced liver grievance in rat through attenuating NF-kB and PI3K/Akt pathwayBo Ma0Sheng Zheng1Ning Xie2Juan Yang3Xueli Zeng4Pei Liu5Shunling Zhang6Ji Li7Department of General Surgery, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, ChinaDepartment of Gastroenterology, The Third People’s Hospital of Yunnan Province, Kunming, Yunnan, ChinaDepartment of Infectious Disease, The 908th Hospital of Chinese People’s Liberation Army Joint Logistic Support Force, Nanchang, Jiangxi, ChinaDepartment of Science and Education, The Third People’s Hospital of Yunnan Province, Kunming, Yunnan, ChinaGraduate School of Clinical Medicine, Dali University, Dali, Yunnan, ChinaGraduate School of Clinical Medicine, Dali University, Dali, Yunnan, ChinaGraduate School of Clinical Medicine, Dali University, Dali, Yunnan, ChinaDepartment of Hepatobiliary Surgery, People’s Hospital of He Chuan ChongQing Chongqing, China; Corresponding author.Background: Metformin (MET) is a dietary polyphenolic compound that exhibits anti-inflammatory and antioxidant properties. This study evaluated the protective effects of MET in both in vitro and in vivo models against potassium bromate (KBrO3)-induced hepatotoxicity. Hepatic cells were exposed to KBrO3 with or without metformin (20, 40, and 60 µM), and cell viability and Reactive Oxygen Species levels were assessed. In vivo, rats were divided into five groups: control, KBrO3, and KBrO3 with metformin (25, 50, and 100 mg/kg). Liver and blood samples were analyzed for histological changes, oxidative stress markers, lipid peroxidation, liver enzymes, and PI3K/Akt signaling. Results: KBrO3 exposure significantly decreased cell viability and increased ROS levels. Co-treatment with MET dose-dependently restored cell viability, with 60 µM MET achieving approximately 80% viability. Metformin also reduced ROS levels, with mean fluorescence intensity approaching control values at higher concentrations. In the in vivo study, KBrO3 exposure elevated lipid peroxidation markers, depleted antioxidant enzyme activities, and triggered oxidative stress and inflammation. Metformin significantly alleviated histological liver damage, suppressed proinflammatory cytokines, enhanced antioxidant enzyme activities, and modulated the PI3K/Akt signaling pathway to promote cell survival and reduce oxidative injury. Conclusions: Metformin effectively protects hepatic cells against KBrO3-induced cytotoxicity by improving cell viability and reducing Reactive Oxygen Species levels. Metformin successfully mitigates KBrO3-induced hepatic injury by reducing oxidative stress, modulating inflammatory pathways (NF-kB), and regulating the PI3K/Akt signaling cascade, offering molecular evidence of its hepatoprotective effects.How to cite: Ma B, Zheng S, Xie N, et al. Metformin mitigates potassium bromate induced liver grievance in rat through attenuating NF-kB and PI3K/Akt pathway. Electron J Biotechnol 2025;76. https://doi.org/10.1016/j.ejbt.2025.03.002.http://www.sciencedirect.com/science/article/pii/S0717345825000144AntiinflammatoryAntioxidant activityHepatic cellsHepatoprotectivityMetforminOxidative stress |
| spellingShingle | Bo Ma Sheng Zheng Ning Xie Juan Yang Xueli Zeng Pei Liu Shunling Zhang Ji Li Metformin mitigates potassium bromate-induced liver grievance in rat through attenuating NF-kB and PI3K/Akt pathway Electronic Journal of Biotechnology Antiinflammatory Antioxidant activity Hepatic cells Hepatoprotectivity Metformin Oxidative stress |
| title | Metformin mitigates potassium bromate-induced liver grievance in rat through attenuating NF-kB and PI3K/Akt pathway |
| title_full | Metformin mitigates potassium bromate-induced liver grievance in rat through attenuating NF-kB and PI3K/Akt pathway |
| title_fullStr | Metformin mitigates potassium bromate-induced liver grievance in rat through attenuating NF-kB and PI3K/Akt pathway |
| title_full_unstemmed | Metformin mitigates potassium bromate-induced liver grievance in rat through attenuating NF-kB and PI3K/Akt pathway |
| title_short | Metformin mitigates potassium bromate-induced liver grievance in rat through attenuating NF-kB and PI3K/Akt pathway |
| title_sort | metformin mitigates potassium bromate induced liver grievance in rat through attenuating nf kb and pi3k akt pathway |
| topic | Antiinflammatory Antioxidant activity Hepatic cells Hepatoprotectivity Metformin Oxidative stress |
| url | http://www.sciencedirect.com/science/article/pii/S0717345825000144 |
| work_keys_str_mv | AT boma metforminmitigatespotassiumbromateinducedlivergrievanceinratthroughattenuatingnfkbandpi3kaktpathway AT shengzheng metforminmitigatespotassiumbromateinducedlivergrievanceinratthroughattenuatingnfkbandpi3kaktpathway AT ningxie metforminmitigatespotassiumbromateinducedlivergrievanceinratthroughattenuatingnfkbandpi3kaktpathway AT juanyang metforminmitigatespotassiumbromateinducedlivergrievanceinratthroughattenuatingnfkbandpi3kaktpathway AT xuelizeng metforminmitigatespotassiumbromateinducedlivergrievanceinratthroughattenuatingnfkbandpi3kaktpathway AT peiliu metforminmitigatespotassiumbromateinducedlivergrievanceinratthroughattenuatingnfkbandpi3kaktpathway AT shunlingzhang metforminmitigatespotassiumbromateinducedlivergrievanceinratthroughattenuatingnfkbandpi3kaktpathway AT jili metforminmitigatespotassiumbromateinducedlivergrievanceinratthroughattenuatingnfkbandpi3kaktpathway |